Penicillamine-induced pemphigus erythematosus.
Pemphigus erythematosus occurred in a patient with rheumatoid arthritis who was treated with D-penicillamine. The skin lesions appeared 4 months after the onset of D-penicillamine treatment and persisted 14 years after cessation of this drug. Topical betamethasone dipropionate applications resulted in complete regression of the cutaneous lesions.
Willemsen
M J
MJ
Department of Dermatology, Akademisch Ziekenhuis Vrije Universiteit Brussels, Belgium.
De Coninck
A L
AL
De Raeve
L E
LE
Roseeuw
D I
DI
D000279:Administration, Cutaneous; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005455:Fluorescent Antibody Technique; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000276:immunology; D010396:Penicillamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000031:analogs & derivatives; D012867:Skin / Q000276:immunology / Q000473:pathology
D007075:Immunoglobulin M; C036069:penicillamine disulfide; D001623:Betamethasone; D010396:Penicillamine